This week, James Stevenson, PharmD, FASHP, professor at the University of Michigan College of Pharmacy, delivered a webinar via the Academy of Managed Care Pharmacy.
This week, James Stevenson, PharmD, FASHP, professor at the University of Michigan College of Pharmacy, delivered a webinar via the Academy of Managed Care Pharmacy. The outset of the webinar focused on familiarizing pharmacists with key facts concerning biosimilars, including the following:
Dr Stevenson also discussed the role of clinical trials for biosimilars, explaining that:
Finally, the webinar addressed the issue of biosimilar interchangeability. Dr Stevenson stressed that the fact that no biosimilars have been deemed interchangeable to date does not indicate that these products are inferior to their references; instead, he said, because the FDA has not yet finalized its guidance on demonstrating interchangeability, there exists no path via which a biosimilar could achieve interchangeable status. He highlighted several important factors that will impact the eventual interchangeability of biosimilars, including the following:
Dr Stevenson said that recent reviews of the literature concerning anti-tumor necrosis factor (anti-TNF) biosimilars support the interchangeability of biosimilar products, and noted that many companies have included at least a single switching arm in their biosimilar trials, even in the absence of FDA guidance. Dr Stevenson's remarks echo those of FDA representatives who have suggested that biosimilars could begin to receive interchangeable designations within the next 2 years.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.